728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

LAS VEGAS, Feb. 5, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) has filed a nonprovisional patent application to protect its cannabinoid-containing complex mixtures for the treatment of inflammatory disorders. The new patent application claims the benefit of GB Sciences’ provisional patent previously filed on February 1, 2017; plus, additional data describing their mechanism of action and further supporting their claims. Inflammatory disorders, such as arthritis, asthma, eczema, psoriasis, Crohn’s disease and Inflammatory Bowel Disease, represent a serious health burden in the US with over $200 billion spent annually. New cannabis-based therapies could significantly help both patients and society.

“Filing this nonprovisional patent signifies our passage to the next phase in the development of these cannabis-based anti-inflammatory compounds, which have the potential to alleviate patient suffering,” explains Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. “We look forward to commercializing the multiple disease-specific anti-inflammatory formulations in this patent application through different channels; including one potential pharmaceutical formulation that may be applied to an orphan indication and another with a nutraceutical-compliant formulation. GB Sciences also plans to develop a series of distinct anti-inflammatory formulations for sale in cannabis dispensaries. Development through different regulatory pathways and sales channels allows us to get some of these therapies to patients quicker and to implement a diversified sales strategy.”

“GB Sciences is committed to developing products that improve peoples’ lives and new anti-inflammatory products are needed as these conditions increase in prevalence,” said John Poss, CEO and Chairman of GB Sciences, Inc. “Providing our patients with cannabis-based products that are designed for dispensary sales will benefit patients in the near term.”

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *